Life sciences news
-
argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis
Thursday September 21st 2023
Read more
-
SwiftPharma and the Population Council Pursue Agreement to Manufacture Griffithsin Needed for the Development of a Fast-Dissolving Insert for Protection Against HIV
Friday September 8th 2023
Read more
-
SwiftPharma and AntoXa Corporation sign exclusive collaboration agreement to support the development and commercialization of a plant-made antibody against ricin exposure
Friday September 1st 2023
Read more
-
AI assists in arthritis diagnosis based on MRI images
Monday August 28th 2023
Read more
-
argenx reports positive topline data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy
Monday July 17th 2023
Read more
-
VUB neurologist argues for affordability of new Alzheimer’s drug
Friday July 14th 2023
Read more
-
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
Monday July 10th 2023
Read more
-
argenx and Zai Lab announce approval of VYVGART® (efgartigimod alfa injection) for generalized myasthenia gravis in China
Friday June 30th 2023
Read more
-
Become a flanders.bio member
Your news here?
-
argenx announces U.S. Food and Drug Administration approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in generalized myasthenia gravis
Wednesday June 21st 2023
Read more
-
Oxurion finalizes enrollment in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema
Monday June 12th 2023
Read more
-
Scientists shed light on a sleep peptide involved in Alzheimer’s
Wednesday May 17th 2023
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
